Study of the guidelines and approaches of breast carcinoma management during the COVID-19 pandemic

Abstract

Author(s): Yousif Abdallah*

Background: The pandemic COVID-19 has had a significant impact on cancer treatment. Several non-urgent hospital operations have been delayed reducing SARS-CoV-2 exposures, and patient visits to health centres have decreased. As a public health measure, careful consideration should be given to whether to prescribe immunosuppressive medications considering the current outbreak. Due to the delay of many breast surgeries, neoadjuvant systemic therapy is increasingly used for breast cancer.

Materials and Methods: In some cases, the augmented application of genetic tumour reporting may be necessary to guide neoadjuvant treatment options for core biopsy specimens. To successfully implement breast carcinoma management during a pandemic, health professionals require multidisciplinary teamwork. This can vary in terms of the different phases, tumour type, patient general condition and performance comorbidities and hospital resources. This paper describes how the COVID19 epidemic of the females' cancers program is handled in breast carcinoma.

Results: In this study, algorithms were used to guideline tumour biology and the severity of pandemic control options, which were then tested. They are primarily concerned with clinical oncology management choices, and they determine that the general therapy guidelines provided by nationwide organizations, such as the COVID-19 Pandemic Breast Cancer Consortium, have become operational throughout the pandemic.

Conclusion: The guidelines presented in this paper can be tailored to meet the needs and resources of other institutions, as well as the practices of oncology. To help control the spread of SARS-CoV-2 and SARS-CoV-2 breast cancer therapy, these guidelines will be critical.

Share this article